Arcellx (Arcellx) ROCE % : 14.94% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Arcellx ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Arcellx's annualized ROCE % for the quarter that ended in Dec. 2023 was 14.94%.

Arcellx ROCE % Historical Data

The historical data trend for Arcellx's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcellx ROCE % Chart

Arcellx Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-44.33

-69.04

-78.09

-100.77

-13.73

Arcellx Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial										-55.13	-29.12	-20.13	-33.80	14.94

Arcellx ROCE % Calculation

Arcellx's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-66.185	/	( ( (313.817 - 56.693)	+	(825.132 - 118.238) )	/ 2 )
	=	-66.185	/	( (257.124	+	706.894)	/ 2 )
	=	-66.185	/	482.009
	=	-13.73 %

Arcellx's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	85.772	/	( ( (614.218 - 173.149)	+	(825.132 - 118.238) )	/ 2 )
	=	85.772	/	( ( 441.069	+	706.894 )	/ 2 )
	=	85.772	/	573.9815
	=	14.94 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Arcellx (NAS:ACLX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Arcellx ROCE % Related Terms

Thank you for viewing the detailed overview of Arcellx's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Arcellx (Arcellx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcellx Inc (NAS:ACLX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

25 West Watkins Mill Road, Suite A, Gaithersburg, MD, USA, 20878

Website

https://www.arcellx.com

Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.

Executives

Michelle Gilson	officer: Chief Financial Officer	25 WEST WATKINS MILL ROAD, SUITE A, GAITHERSBURG MD 20878
Christopher Heery	officer: Chief Medical Officer	C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Rami Elghandour	director, officer: See Remarks	15 BARCELONA CIR, REDWOOD CITY CA 94065
Jill Carroll	director	C/O APPLIED GENETIC TECHNOLOGIES CORP., 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615
Sr One Capital Fund I Aggregator Lp	10 percent owner	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Scott D Sandell	10 percent owner
Forest Baskett	10 percent owner
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
New Enterprise Associates 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Olivia C Ware	director	11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Sr One Capital Management, Llc	10 percent owner	985 OLD EAGLE SCHOOL ROAD, SUITE 511, WAYNE PA 19087
Sr One Co-invest Ii Manager, Llc	10 percent owner	985 OLD EAGLE SCHOOL ROAD, SUITE 511, WAYNE PA 19087
Nea Partners 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093